Biotech Myeloid Therapeutics Announces SITC 2024 Oral Presentation on MT-303, the First in vivo GPC3 Targeting mRNA CAR in Human Studies for Advanced Hepatocellular Carcinoma (HCC) November 9, 2024
Biotech WILLOW BIOSCIENCES ANNOUNCES NEW PARTNERSHIP WITH A GLOBAL INGREDIENT MANUFACTURER TO ADVANCE DEVELOPMENT OF A HIGH VALUE INGREDIENT FROM ITS PORTFOLIO November 8, 2024
Biotech Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial November 8, 2024
Biotech Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations November 8, 2024
Biotech Naitive® and Parvizi Surgical Innovation Partner to Advance Osteoporosis Detection November 7, 2024
Biotech Genezen Welcomes Industry Experts Dr. Pam Stetkiewicz and Stuart Auerbach to Board of Directors November 7, 2024
Biotech Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders November 7, 2024
Biotech Leads Biolabs Receives Orphan Drug Designation from the US FDA for LBL-034, a Uniquely Designed, Highly Differentiated Anti-GPRC5D/CD3 Bispecific Antibody, for the Treatment of Multiple Myeloma November 6, 2024
Biotech ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma’s Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report November 6, 2024
Biotech Minghui Pharmaceutical Announces Promising Initial Results from Phase I Clinical Trial of MHB039A, a Novel PD-1 x VEGF Bispecific Antibody, in Patients with Relapsed/Refractory Solid Tumors November 6, 2024
Search
Biotech
November 9, 2024
November 8, 2024
November 8, 2024
November 8, 2024
November 7, 2024
November 7, 2024
November 7, 2024
November 6, 2024
November 6, 2024
November 6, 2024
